A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment

A Randomized, Double-Blind, Placebo- and Active-Controlled, Multi-Center Study to Assess the Antipsychotic Efficacy of ITI-007 After 6 Weeks of Treatment in Patients With Schizophrenia

The study will evaluate the antipsychotic efficacy of ITI-007 in a randomized, double-blind, parallel-group, placebo- and active-controlled, multi-center study in patients diagnosed with schizophrenia having an acute exacerbation of psychosis.

Inclusion Criteria:

• male or female subjects of any race, ages 18-60 inclusive, with a clinical diagnosis of schizophrenia
• experiencing an acute exacerbation of psychosis

Exclusion Criteria:

• any subject unable to provide informed consent
• any female subject who is pregnant or breast-feeding
• any subject judged to be medically inappropriate for study participation